Cell Therapeutics Expects 2007 NDA Filing For Xyotax
This article was originally published in The Pink Sheet Daily
Executive Summary
Company plans to utilize interim data from ongoing PIONEER trial in its submission for the lung cancer treatment for women.
You may also be interested in...
Novartis And Cell Therapeutics Suspend Xyotax Development
CTI and Novartis are temporarily suspending the PIONEER lung cancer trial to evaluate mortality signals and amend the study protocol.
Novartis And Cell Therapeutics Suspend Xyotax Development
CTI and Novartis are temporarily suspending the PIONEER lung cancer trial to evaluate mortality signals and amend the study protocol.
Novartis Signs Development Deal With Cell Therapeutics For Xyotax
Novartis and CTI will develop and commercialize poliglumex paclitaxel, currently in Phase III for non-small cell lung cancer in women.